What are the AASLD guidelines for the treatment of adults with HBeAg-negative immune-active chronic hepatitis B (HBV) (Hep B) infection?

Updated: Aug 01, 2018
  • Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF; Chief Editor: BS Anand, MD  more...
  • Print
Answer

The AASLD suggests indefinite antiviral therapy for adults with HBeAg-negative immune-active chronic hepatitis B infection, unless there is a competing rationale for treatment discontinuation. (Conditional recommendation) If antiviral therapy is stopped, monitor the patient every 3 months for a minimum of 1 year for recurrent viremia, ALT flares, and clinical decompensation.

Antiviral therapy is not recommended for noncirrhotic individuals who are HBeAg negative and who have normal ALT activity and low-level viremia (< 2,000 U/mL; “inactive chronic hepatitis B”).


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!